Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection
Abstract Ivermectin is an antiparasitic drug being investigated for repurposing to SARS-CoV-2. In-vitro, ivermectin showed limited antiviral activity and a COVID-19 animal model demonstrated pathological benefits but no effect on viral RNA. This meta-analysis investigated ivermectin in 18 randomized clinical trials (2282 patients) identified through systematic searches of PUBMED, EMBASE, MedRxiv and trial registries. Ivermectin was associated with reduced inflammatory markers (C-Reactive Protein, d-dimer and ferritin) and faster viral clearance by PCR. Viral clearance was treatment dose- and duration-dependent. In six randomized trials of moderate or severe infection, there was a 75% reduction in mortality (Relative Risk=0.25 [95%CI 0.12-0.52]; p=0.0002); 14/650 (2.1%) deaths on ivermectin; 57/597 (9.5%) deaths in controls) with favorable clinical recovery and reduced hospitalization. Many studies included were not peer reviewed and meta-analyses are prone to confounding issues. Ivermectin should be validated in larger, appropriately controlled randomized trials before the results are sufficient for review by regulatory authorities..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
ResearchSquare.com - (2022) vom: 29. Juli Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.21203/rs.3.rs-148845/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA034838023 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA034838023 | ||
| 003 | DE-627 | ||
| 005 | 20230429174141.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220113s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-148845/v1 |2 doi | |
| 035 | |a (DE-627)XRA034838023 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-148845/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hill, Andrew |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Ivermectin is an antiparasitic drug being investigated for repurposing to SARS-CoV-2. In-vitro, ivermectin showed limited antiviral activity and a COVID-19 animal model demonstrated pathological benefits but no effect on viral RNA. This meta-analysis investigated ivermectin in 18 randomized clinical trials (2282 patients) identified through systematic searches of PUBMED, EMBASE, MedRxiv and trial registries. Ivermectin was associated with reduced inflammatory markers (C-Reactive Protein, d-dimer and ferritin) and faster viral clearance by PCR. Viral clearance was treatment dose- and duration-dependent. In six randomized trials of moderate or severe infection, there was a 75% reduction in mortality (Relative Risk=0.25 [95%CI 0.12-0.52]; p=0.0002); 14/650 (2.1%) deaths on ivermectin; 57/597 (9.5%) deaths in controls) with favorable clinical recovery and reduced hospitalization. Many studies included were not peer reviewed and meta-analyses are prone to confounding issues. Ivermectin should be validated in larger, appropriately controlled randomized trials before the results are sufficient for review by regulatory authorities. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Abdulamir, Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed, Sabeena |e verfasserin |4 aut | |
| 700 | 1 | |a Asghar, Asma |e verfasserin |4 aut | |
| 700 | 1 | |a Babalola, Olufemi Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Basri, Rabia |e verfasserin |4 aut | |
| 700 | 1 | |a Chaccour, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Chachar, Aijaz Zeeshan Khan |e verfasserin |4 aut | |
| 700 | 1 | |a Chowdhury, Abu Tauib Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Elgazzar, Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a Ellis, Leah |e verfasserin |4 aut | |
| 700 | 1 | |a Falconer, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Garratt, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Hany, Basma |e verfasserin |4 aut | |
| 700 | 1 | |a Hashim, Hashim A |e verfasserin |4 aut | |
| 700 | 1 | |a Haque, Wasim Ul |e verfasserin |4 aut | |
| 700 | 1 | |a Hayat, Arshad |e verfasserin |4 aut | |
| 700 | 1 | |a He, Shuixiang |e verfasserin |4 aut | |
| 700 | 1 | |a Jamshidian, Ramin |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Wasif Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Kirti, Ravi |e verfasserin |4 aut | |
| 700 | 1 | |a Krolewiecki, Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Lanusse, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Levi, Jacob |e verfasserin |4 aut | |
| 700 | 1 | |a Mahmud, Reaz |e verfasserin |4 aut | |
| 700 | 1 | |a Mangat, Sermand Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a McCann, Kaitlyn |e verfasserin |4 aut | |
| 700 | 1 | |a Mohan, Anant |e verfasserin |4 aut | |
| 700 | 1 | |a Niaee, Mortezza Shakshi |e verfasserin |4 aut | |
| 700 | 1 | |a Okumus, Nurullah |e verfasserin |4 aut | |
| 700 | 1 | |a Pilkington, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Podder, Chinmay Saha |e verfasserin |4 aut | |
| 700 | 1 | |a Qavi, Ambar |e verfasserin |4 aut | |
| 700 | 1 | |a Raad, Houssam |e verfasserin |4 aut | |
| 700 | 1 | |a Rezai, Mohammaed Sadegh |e verfasserin |4 aut | |
| 700 | 1 | |a Sasank, Surapaneni |e verfasserin |4 aut | |
| 700 | 1 | |a Spoorthi, Veerapaneni |e verfasserin |4 aut | |
| 700 | 1 | |a Suri, Tejas |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Junzheng |e verfasserin |4 aut | |
| 700 | 1 | |a Wentzel, Hannah |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2022) vom: 29. Juli |
| 773 | 1 | 8 | |g year:2022 |g day:29 |g month:07 |
| 856 | 4 | 0 | |u https://doi.org/10.1093/ofid/ofab358 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-148845/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 29 |c 07 | ||